Anticancer drugs: Targeting triple-negative breast cancer

Nature Reviews Drug Discovery

Volumn 8, Issue 1, 2009, Pages 21-

  Kirkpatrick, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988044989     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2789     Document Type: Article

References (4)

1. Rottenberg, S. et al. High sensitivity of BRCAl-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008)
2. Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104, 12111-12116 (2007)
3. Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104, 12117-12122 (2007)
4. Sharpless, N. E. & DePinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev. Drug Discov. 5, 741-754 (2006)